Evogene Ltd. and Shanghai Lishan Biopharmaceuticals Co., Ltd. have announced an exclusive worldwide licensing agreement for BMC128, a microbiome-based therapeutic developed by Biomica Ltd., a subsidiary of Evogene. Under the terms of the agreement, Lishan Biotech will be responsible for the global clinical development, manufacturing, and commercialization of BMC128. Biomica will be eligible for development milestone payments and royalties on future commercial sales according to an agreed schedule. BMC128 is currently completing a Phase 1 clinical study in renal cell carcinoma and non-small cell lung cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief on February 04, 2026, and is solely responsible for the information contained therein.